DOXANANO is an early stage company that develops a breakthrough first line treatment for patients suffering from locally advanced tumours. We develop a unique nano-release platform that will allow, after systemic injection, to locally increase the quantity of cytotoxic drugs into the tumour compared to the same injected free-drug, while preserving healthy organs. We call our breakthrough approach Remotely Activated Chemotherapy (RAC).

Contact :

CEO : Isabel Marey-Semper  contact@doxanano.com

Website : www.doxanano.com

Targeted indications : lung cancer, colorectal cancer, head & neck cancer, gastrointestinal cancer